Protheragen, a US-based company specializing in providing exceptional business development and transaction intermediary services, extends its warm congratulations to Serpentide for being selected to collaborate with Novo Nordisk through their Co-Creation Greenhouse Program. This exciting partnership aims to advance novel treatments for obesity and diabetes through the application of Serpentide’s innovative SHIELD (Sustained Half-life, Stable Release, Scalable Production) technology platform.
Serpentide’s SHIELD platform has demonstrated significant potential in enhancing the efficacy and scalability of peptide drugs by extending their half-life and minimizing side effects. The ability to scale production while ensuring therapeutic stability is a critical advancement in peptide drug development, making this collaboration a meaningful step in addressing the growing challenges of chronic conditions like obesity and diabetes.
Protheragen recognizes the importance of collaborations like the one Serpentide has formed with Novo Nordisk in advancing global health. Such innovative efforts in biotechnology inspire us to continue working toward the development of groundbreaking solutions in the realm of precision medicine and beyond. We look forward to seeing how Serpentide’s work progresses and the profound impact this collaboration will have on the future of chronic disease treatment.
Protheragen has accumulated extensive industry resources and possesses profound insights into the cutting-edge developments in biotechnology and pharmaceuticals. We adhere to a flexible and efficient cooperation model, excelling at building wide-ranging industry connections and actively facilitating indepth collaborations among all parties.
We are eagerly looking forward to having the opportunity to have in-depth communication with you and explore the possibilities of collaboration. Please feel free to contact us.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |